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Introduction {#sec005}
============

Head and neck squamous cell carcinoma(HNSCC)is the sixth most common cancer worldwide \[[@pone.0173194.ref001]\]. More than 500,000new HNSCC cases are diagnosed each year, which include two-thirds of the patients diagnosed with advanced stage, lymph node metastasis \[[@pone.0173194.ref002]\]. Moreover, the five-year survival of patients with HNSCC remains about 40--50% \[[@pone.0173194.ref002]\].The molecular mechanisms associated with the pathogenesis of HNSCC comprise of a variety of genetic alterations such as mutations and epigenetic modifications, including methylation of CpG islands. In addition, the epigenetic modification resulting in the alteration of expression of tumor-related genes is considered crucial in the development of HNSCC \[[@pone.0173194.ref003],[@pone.0173194.ref004]\].

The promoter methylation of the tumor suppressor gene (TSG) leads to gene inactivation, which reduces or inhibits the function of the tumor suppressor. Hypermethylation of the tumor suppressor gene occurs in cancer development for many types of cancers including HNSCC. The death-associated protein kinase (*DAPK*) is a tumor suppressor gene, which is a mediator of cell death of INF-γ--induced apoptosis \[[@pone.0173194.ref005]--[@pone.0173194.ref007]\]. The decreased expression of *DAPK* is associated with the methylation of gene promoter \[[@pone.0173194.ref008],[@pone.0173194.ref009]\]. The methylation of *DAPK* promoter has been found to be an important epigenetic modification in several types of cancers \[[@pone.0173194.ref010]--[@pone.0173194.ref012]\].

Aberrant methylation of *DAPK* promoter has been reported in patients with HNSCC. However, the results are inconsistent. There are significant differences in the frequency of *DAPK* promoter methylationin patients with HNSCC. Moreover, whether the methylation frequency of *DAPK* promoter is correlated with clinicopathological features (sex, smoking status, alcohol status and lymph node invasion) in HNSCC patients remains unclear. Thus, we performed the meta-analysis to investigate the relationship between the methylation status of *DAPK* promoter and HNSCC, as well as the relationship between *DAPK* promoter methylation and clinicopathological features of HNSCC.

Materials and methods {#sec006}
=====================

The meta-analysis was performed according to the latest meta-analysis guidelines (PRISMA) \[[@pone.0173194.ref013]\].

Search strategy {#sec007}
---------------

Systematic review of relevant literature was conducted using PubMed, Web of Science, Ovid, and Embase databases from January 1, 1968, to June 30, 2016. The keywords used for the literature search were: (*DAPK* methylation) and (head and neck or oral or tonsil ororopharyngeal or laryngeal or oropharynx) and (squamous cell carcinoma or cancer).

Inclusion and exclusion criteria of literature {#sec008}
----------------------------------------------

The studies were included if they satisfied the following inclusion criteria: (1) investigated the correlation between *DAPK* promoter methylation and HNSCC or investigated the correlation between *DAPK* promoter methylation and clinicopathological features,(2) specimens of case group (HNSCC) were limited to tissues, (3) the *DAPK* promoter methylation frequency and sample size provided in the case and the control groups.

Only studies written in English were included for review. In addition, case reports, abstracts, and letters to the editor were eliminated.

Data extraction and quality assessment {#sec009}
--------------------------------------

The relevant data from the eligible studies were independently retrieved by two authors (Fucheng Cai and Yi Zhong). The relevant data include the name of the first author, year of publication, region of study subjects, age of patients, methylation detection method, source of control, type of samples in the control group, number of people with *DAPK* methylation in case and control groups, and sample size of case and control groups. Moreover, we also extracted the number of individuals with *DAPK* methylation in clinical features' subgroups in the studies investigating the correlation between *DAPK* promoter methylation and clinical characteristics of HNSCC. The third reviewer (Xiyue Xiao) independently reviewed the relevant data extracted from the eligible studies.

Statistical analysis {#sec010}
--------------------

The strength of the association between *DAPK* promoter methylation and HNSCC was evaluated by odds ratio (OR) with 95% confidence intervals (CIs).The degree of association between *DAPK* promoter methylation and clinicopathological features was also evaluated by OR with 95%CI.The heterogeneity among the included studies was estimated by the Cochran Q test and *I*^*2*^ statistics \[[@pone.0173194.ref014]\].The random-effects model was used to compute the pooled ORs when the heterogeneity was considered significant (*P*\<0.05 for the Q statistic). In the case of a different scenario, a fixed-effects model was applied to compute the pooled ORs. To explore the potential source of heterogeneity among the included studies, meta-regression analyses, and subgroup analyses were conducted. A sensitivity analysis was employed to assess the influence of each study excluded in the combined OR. The publication bias was assessed by the Begg's funnel plot \[[@pone.0173194.ref015]\]and Egger's test \[[@pone.0173194.ref016]\]. The reported P values were two-sided for all the analyses. 0.5 is added as a default to all 0 counts when the 2×2 table for the individual studies contains cells with 0 counts in the Meta package. All statistical tests were performed using the Meta package in R (version 3.2.3; <http://www.r-project.org/>).

Results {#sec011}
=======

Identification of studies and study characteristics {#sec012}
---------------------------------------------------

A total of 188 studies were initially identified by literature search. The duplicates and non-relevant studies (reviews and animal and cell studies) were excluded by considering the title and abstract of the studies. 28 articles with potentially relevant studies were further identified by examining the full text. Finally, 18 studies were included in the meta-analysis after excluding studies without methylation frequency and tissues in the case group. The detailed study selection process is illustrated in [Fig 1](#pone.0173194.g001){ref-type="fig"}.

![Flow chart of studies included in the meta-analysis.](pone.0173194.g001){#pone.0173194.g001}

Out of the 18 studies included, 15 studies with 818 cases and 852 controls were combined to calculate the pooled OR between *DAPK* promoter methylation and HNSCC. The 15 studies encompassed the publication years from 2002--2015. The methylation detection methods consisted of the methylation-specific polymerase chain reaction (MSP), real-time quantitative MSP (QMSP), and bisulfite sequencing PCR (BSP). Among the 15 included studies, 10 studies used MSP, 4 studies used QMSP and 1 study used BSP to explore *DAPK* promoter methylation in HNSCC and corresponding control. Eight studies were of Asian subjects and seven studies were of non-Asian subjects. The sample of controls consisted of tissue, blood, saliva, and buccal scrapings. The control source contained autologous and heterogeneous controls. The detail study characteristics were summarized in [Table 1](#pone.0173194.t001){ref-type="table"}.

10.1371/journal.pone.0173194.t001

###### Characteristics of studies included in the meta-analysis of *DAPK* promoter methylation and HNSCC.

![](pone.0173194.t001){#pone.0173194.t001g}

  author                                           year   region    age (case, years)            case   control   method[^\#^](#t001fn002){ref-type="table-fn"}   control source[\*](#t001fn003){ref-type="table-fn"}   control sample       
  ------------------------------------------------ ------ --------- ---------------------------- ------ --------- ----------------------------------------------- ----------------------------------------------------- ---------------- --- ------------------
  Arantes, L. M.\[[@pone.0173194.ref021]\]         2015   Brazil    median = 54.5;range:41--78   32     8         8                                               32                                                    QMSP             H   saliva
  Choudhury, J. H.\[[@pone.0173194.ref022]\]       2015   India     range:23--86                 21     50        5                                               40                                                    MSP              A   tissue
  Rettori, M. M.\[[@pone.0173194.ref023]\]         2013   Brazil    median = 59;range:20--90     35     33        1                                               38                                                    QMSP             H   saliva
  Li, C.\[[@pone.0173194.ref008]\]                 2013   China     median = 55;range:40--72     30     23        0                                               23                                                    MSP              H   tissue
  Liu, Y.\[[@pone.0173194.ref024]\]                2012   China     mean = 55.0; sd: 13.5        15     17        15                                              62                                                    QMSP             H   tissue
                                                                                                                  16                                              61                                                                         blood
                                                                                                                  2                                               75                                                                         saliva
  Paluszczak, J.\[[@pone.0173194.ref025]\]         2011   Poland    mean = 58.3;range:41--75     31     10        32                                              9                                                     MSP              A   tissue
  Wong, Y.K.\[[@pone.0173194.ref026]\]             2011   Taiwan    mean = 51.7;range:26--77     29     35        26                                              38                                                    MSP              A   tissue
                                                                                                                  0                                               20                                                                     H   tissue
  Laytragoon-Lewin, N.\[[@pone.0173194.ref027]\]   2010   Sweden    median = 62;range:42--101    7      11        2                                               16                                                    MSP              A   tissue
  Su, P. F.\[[@pone.0173194.ref028]\]              2010   Taiwan    mean = 54.94;range:37--82    13     18        5                                               26                                                    QMSP             A   tissue
                                                                                                                  0                                               12                                                                     H   buccal scrapings
  Steinmann, K.\[[@pone.0173194.ref029]\]          2009   Germany   mean = 57;range:41--71       36     18        8                                               15                                                    MSP              A   tissue
  De Schutter, H.\[[@pone.0173194.ref030]\]        2009   Belgium   mean = 59;range:43--76       4      40        2                                               3                                                     MSP              H   tissue
  Righini, C. A.\[[@pone.0173194.ref031]\]         2007   French    median = 57;range:33--74     19     71        1                                               29                                                    MSP              A   tissue
                                                                                                                  9                                               51                                                                     A   saliva
                                                                                                                  0                                               30                                                                     H   saliva
  Kong, W. J.\[[@pone.0173194.ref032]\]            2005   China     mean = 53.3;range:32--78     39     19        6                                               52                                                    MSP              A   tissue
  Kulkarni, V.\[[@pone.0173194.ref033]\]           2004   India     median = 50;range:25--71     41     19        36                                              24                                                    MSP              A   tissue
                                                                                                                  0                                               20                                                                     H   buccal scrapings
  Ogi, K.\[[@pone.0173194.ref017]\]                2002   Japan     NA                           7      89        0                                               2                                                     BSR              H   tissue

M: *DAPK* promoter methylated, U: *DAPK* promoter unmethylated

\#: MSP: methylation-specific polymerase chain reaction, QMSP: real-time quantitative MSP, BSP: Bisulfite sequencing PCR

\*: A: Autologous control, H: Heterogeneous control

Among the 18 included studies, seven studies were combined to estimate the pooled OR between *DAPK* promoter methylation and clinicopathological features of HNSCC from the 18 included studies. The clinicopathological features included sex, smoking status, alcohol status, and lymph node invasion. The detailed characteristics of the study were summarized in [Table 2](#pone.0173194.t002){ref-type="table"}.

10.1371/journal.pone.0173194.t002

###### Characteristics of studies included in themeta-analysis of *DAPK* promoter methylation and clinicopathological features.

![](pone.0173194.t002){#pone.0173194.t002g}

  Author                                     Year   Region     Method[^\#^](#t002fn002){ref-type="table-fn"}   Sex     Smoking   Alcohol   N_stage[\*](#t002fn003){ref-type="table-fn"}                           
  ------------------------------------------ ------ ---------- ----------------------------------------------- ------- --------- --------- ---------------------------------------------- ------- ------- ------- -------
  Misawa, K.\[[@pone.0173194.ref034]\]       2016   Japan      QMSP                                            54/55   17/7      53/42     18/20                                          51/36   20/26   31/28   31/28
  Arantes, L. M.\[[@pone.0173194.ref021]\]   2015   Brazil     QMSP                                            29/7    3/1       26/3      6/5                                            22/4    10/4    9/2     23/6
  Pierini, S.\[[@pone.0173194.ref035]\]      2014   Bulgaria   MS-HRM                                          37/54   4/2       28/44     13/12                                                          29/43   12/13
  Wong, Y.K.\[[@pone.0173194.ref026]\]       2011   Taiwan     MSP                                             25/33   4/2       20/30     7/7                                            18/22   5/9             
  Su, P. F.\[[@pone.0173194.ref028]\]        2010   Taiwan     QMSP                                            12/17   2/2       11/13     3/5                                            8/9     3/8     5/6     9/13
  Supic, G.\[[@pone.0173194.ref036]\]        2009   Serbia     MSP                                             25/39   3/10      22/39     6/10                                                           4/12    24/37
  Kulkarni, V.\[[@pone.0173194.ref033]\]     2004   India      MSP                                             29/15   12/4                                                                               22/10   19/9

M: *DAPK* promoter methylated, U: *DAPK* promoter unmethylated

\#: MSP: methylation-specific polymerase chain reaction, QMSP: real-time quantitative MSP, MS_HRM: Methylation-sensitive high resolution melting

\*: N_stage: lymph node invasion

Association between *DAPK* promoter methylation and HNSCC {#sec013}
---------------------------------------------------------

In the meta-analysis, the heterogeneity among the included studies was significant for Q test (P\<0.001). Thus, the random-effect model was employed to evaluate the summary of ORs. In the random-effect model, we found that *DAPK* promoter methylation was significantly associated with HNSCC (pooled OR = 3.96,95%CI = 2.26--6.95) ([Fig 2](#pone.0173194.g002){ref-type="fig"}).

![Forest plots of *DAPK* promoter methylation associated with HNSCC.](pone.0173194.g002){#pone.0173194.g002}

Association between *DAPK* promoter methylation with clinicopathological features {#sec014}
---------------------------------------------------------------------------------

The meta-analysis result suggested that the frequency of DAPK promoter methylation in patients with HNSCC was significantly higher than the corresponding controls ([Fig 2](#pone.0173194.g002){ref-type="fig"}).Therefore, we also assessed the association between *DAPK* promoter methylation and the clinicopathological features. Among the included studies, the smoking group was divided into three groups (Current, Former, and Never) in three studies. The smoking group in the three studies was divided into two groups (Smoker and Non-smoker). To pool the data, the Current group was classified as Smoker group, and the Former and Never groups were classified as Non-smoker group. In the meta-analysis, *DAPK* promoter methylation was not significantly correlated with sex, smoking status, and lymph node invasion ([Fig 3A, 3B and 3D](#pone.0173194.g003){ref-type="fig"}). However, the meta-analysis found that *DAPK* promoter methylation was significantly correlated with the alcohol status (OR = 1.85, 95% CI = 1.07--3.21) ([Fig 3C](#pone.0173194.g003){ref-type="fig"}).

![Forest plots of *DAPK* promoter methylation associated with clinicopathological features\
A: Forest plots of *DAPK* promoter methylation associated with sex B: Forest plots of *DAPK* promoter methylation associated with smoking status C: Forest plots of *DAPK* promoter methylation associated with alcohol status D: Forest plots of *DAPK* promoter methylation associated with lymph node invasion.](pone.0173194.g003){#pone.0173194.g003}

Meta-regression analysis and subgroup analysis {#sec015}
----------------------------------------------

The meta-regression analysis was used to explore the potential sources of heterogeneity among the included studies. We found that the possible source of heterogeneity was the method (*P* = 0.04) according to the meta-regression analysis ([Table 3](#pone.0173194.t003){ref-type="table"}). To further assess the potential sources, we conducted the subgroup analysis according to the region, methylation detection method, control source, control sample type, and sample size of the case group.

10.1371/journal.pone.0173194.t003

###### Meta-regression analysisof *DAPK* promoter methylation and HNSCC.

![](pone.0173194.t003){#pone.0173194.t003g}

                              95%CI             
  ------------------ -------- -------- -------- -------
  Publication year   0.062    -0.115   0.239    0.495
  Region             -0.881   -2.125   0.363    0.165
  Method             -1.825   -3.590   -0.060   0.043
  Case sample size   -0.767   -2.113   0.580    0.265
  Control source     1.256    -0.417   2.929    0.141
  Control sample     -1.474   -3.033   0.086    0.064

With respect to the subgroups categorized by the region, significant association between *DAPK* promoter methylation and HNSCC was found among the Asian region and the Non-Asia region in the random-effect model (Asian region, OR = 4.43, 95% CI = 2.29--8.58; Non-Asia region, OR = 3.39, 95% CI = 1.18--9.78).The heterogeneity did not decrease remarkably among the region-based subgroup. In the methylation detection method group, Ogi et al.\[[@pone.0173194.ref017]\] used bisulfite-PCR (BSP) to detect methylation and was classified as the MSP group.

The significant association between *DAPK* promoter methylation and HNSCC was displayed among the MSP in the random-effect model and the QMSP in the fixed-effect model (MSP, OR = 2.97, 95% CI = 1.55--5.70; QMSP, OR = 8.84, 95% CI = 5.22--14.99). In the control source, the significant association between *DAPK* promoter methylation and HNSCC was seen among the autologous group and the heterogeneous group in the random-effect model (autologous group, OR = 2.71, 95% CI = 1.49--4.93; heterogeneous group, OR = 9.50, 95% CI = 2.98--30.27). With the control sample type, a significant association between *DAPK* promoter methylation and HNSCC was found among the tissue group and the non-tissue group in the random-effect model (tissue group, OR = 3.95, 95% CI = 1.89--8.25; non-tissue group, OR = 5.30, 95% CI = 2.17--12.93). With the sample size in the cases, significant association between *DAPK* promoter methylation and HNSCC was found among the \<60group in random-effect model and the ≥60 group in the fixed-effect model (\<60 group, OR = 4.64, 95% CI = 1.94--11.06; ≥60 group, OR = 3.12, 95% CI = 2.17--4.49). The subgroup analysis of *DAPK* promoter methylation associated with HNSCC was summarized in [Table 4](#pone.0173194.t004){ref-type="table"}.

10.1371/journal.pone.0173194.t004

###### Summary of the subgroup analysisin the meta-analysis of *DAPK* promoter methylation and HNSCC.

![](pone.0173194.t004){#pone.0173194.t004g}

  Group                     Case   Control   Fixed-effects model   Random-effects model   Heterogeneity                                               
  ------------------------- ------ --------- --------------------- ---------------------- --------------------- -------------------- ------ --------- ------
  Total                     359    820       174                   852                    4.09 (3.17--5.28)     3.96 (2.26--6.95)    72.7   \<0.001   0.79
  Region                                                                                                                                              
  Asia                      195    465       111                   566                    4.21 (3.04--5.84)     4.43 (2.29--8.58)    67.4   0.003     0.53
  Non-asia                  164    355       63                    286                    3.91 (2.60--5.90)     3.39 (1.18--9.78)    79.8   \<0.001   1.53
  Method                                                                                                                                              
  MSP                       257    553       127                   497                    3.18 (2.37--4.28)     2.97 (1.55--5.70)    72.8   \<0.001   0.72
  QMSP                      102    267       47                    355                    8.84 (5.22--14.99)    7.73 (3.09--19.36)   56.4   0.06      0.56
  Control source                                                                                                                                      
  Autologous                236    487       130                   430                    2.49 (1.84--3.36)     2.71 (1.49--4.93)    70.3   0.001     0.56
  Heterogeneous             225    578       44                    442                    11.46 (6.85--19.18)   9.50 (2.98--30.27)   70.8   \<0.001   2.12
  Control sample type^\$^                                                                                                                             
  Tissue                    292    712       138                   497                    3.41 (2.55--4.54)     3.95 (1.89--8.25)    75.4   \<0.001   1.14
  Non-tissue                155    321       36                    355                    6.31 (4.09--9.73)     5.30 (2.17--12.93)   69.8   0.002     1.03
  Case sample size                                                                                                                                    
  \<60                      207    371       96                    482                    5.35 (3.72--7.71)     4.64 (1.94--11.06)   77.8   \<0.001   1.27
  ≥60                       152    449       78                    370                    3.12 (2.17--4.49)     2.94 (1.60--5.38)    50.9   0.070     0.26

M+: *DAPK* promoter methylated

N: total number

Sensitivity analysis {#sec016}
--------------------

The sensitivity analysis was performed to evaluate the stability of the conclusions according to the leave-one-out method by excluding one study. The pooled OR was changed from 3.47 (95%CI = 2.01--6.00) to 4.53(95%CI = 2.67--7.70) under the random-effect model, which confirms the stability of the results ([Fig 4](#pone.0173194.g004){ref-type="fig"}). Therefore, the result of the meta-analysis was stable and reliable.

![Sensitivity analysis of *DAPK* promoter methylation and HNSCC by the random-effects method.](pone.0173194.g004){#pone.0173194.g004}

Publication bias {#sec017}
----------------

Publication bias of the included studies was assessed through the Begg's funnel plot and Egger's test. The shape of the Begg's funnel plot did not reveal any potential asymmetry ([Fig 5](#pone.0173194.g005){ref-type="fig"}). The publication bias detected by Egger's test was not significant (*P* = 0.55).

![Begg's funnel plot of *DAPK* promoter methylation associated with HNSCC.](pone.0173194.g005){#pone.0173194.g005}

Discussion {#sec018}
==========

Hypermethylation of the promoter of the tumor suppressor gene (TSG) resulted in silencing the expression of TSGs in carcinogenesis of the tumor. Death-associated protein kinase (*DAPK*), a tumor suppressor gene, could mediate cell death in INF-γ--induced apoptosis, whereas inactivated *DAPK*, could lead to the pathogenesis and metastasis of the tumor \[[@pone.0173194.ref018]\]. The loss of expression of *DAPK* mainly induced by methylation of its promoter plays a crucial role in the carcinogenesis of the tumor \[[@pone.0173194.ref019]\].

The present meta-analysis including 15 studies was performed to quantitatively assess the strength of association of DAPK promoter methylation and HNSCC. The overall frequency of DAPK promoter methylation in patients with HNSCC was 43.64% and 20.42% in the control population. The results of the meta-analysis suggested that individuals with hypermethylation of DAPK promoter are associated with HNSCC (pooled OR = 3.96, 95%CI = 2.26--6.95).

A significant heterogeneity between the studies was found by Q-test in the meta-analysis. The subgroup analysis was conducted to explore the potential heterogeneity among the included studies in our meta-analysis; a significant association between *DAPK* methylation and HNSCC was found in all the subgroup ([Table 4](#pone.0173194.t004){ref-type="table"}). In the methylation detection method group, a significant association between *DAPK* promoter methylation and HNSCC was observed among the MSP in the random-effect model and the QMSP in the fixed-effect model (MSP, OR = 2.97, 95% CI = 1.55--5.70; QMSP, OR = 8.84, 95% CI = 5.22--14.99). The pooled ORs in QMSP were higher than in the MSP. The phenomenon could be attributed tothe specificity and sensitivity of QMSP detecting up to 1/1000 methylated alleles more than the conventional MSP \[[@pone.0173194.ref020]\]. With the control source, the significant association between *DAPK* promoter methylation and HNSCC was found among the autologous group and the heterogeneous group in the random-effect model (autologous group, OR = 2.71, 95% CI = 1.49--4.93; heterogeneous group, OR = 9.50, 95% CI = 2.98--30.27).The results suggested that the frequency of *DAPK* promoter methylationin the autologous control was higher than the heterogeneous control. This indicated that the *DAPK* promoter methylation might play a crucial role in the pathogenesis of HNSCC.

We also investigated the correlation between the *DAPK* promoter methylation and the clinicopathological features. The results suggested that *DAPK* promoter methylation was significantly correlated with the alcohol status. The drinkers have a 1.85-fold increased *DAPK* methylation frequency compared with the non-drinkers (OR = 1.85, 95% CI = 1.07--3.21). The *DAPK* promoter methylation was not significantly correlated with sex, smoking, and lymph node invasion.

However, the present meta-analysis exhibited some limitations. First, a limited number of articles were included in the meta-analysis for assessing the correlation between *DAPK* promoter methylation and clinicopathological features. Thus, the accurate and reasonable conclusions need to be confirmed in future studies. Second, although the publication bias was not significant according to Egger's test, some unpublished studies and non-English language studies may contribute to some bias.

In conclusion, the present study found that aberrant methylation of *DAPK* promoter was associated with HNSCC, which suggested that the promoter methylation of *DAPK* plays a crucial role in the development of HNSCC. However, well-designed studies with larger sample size may be performed in order to further confirm the correlation between *DAPK* promoter methylation and HNSCC.
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